Cancer metastasis: tumor plasticity counts

November 05, 2019

Cancer metastasis, which is the propagation of tumor cells into distant organs, is the leading cause of cancer patient mortality. To undergo metastasis, cells must leave the primary tumor, invade the microenvironment, circulate into the blood or lymphatic circulation, reach distant organs, and establish a secondary tumor. The precise cellular and molecular events responsible for the different steps of the metastatic cascade are still incompletely understood.

It has been proposed that epithelial to mesenchymal transition (EMT), a process in which epithelial cells detach from their neighboring cells, lose their adhesion features and acquire mesenchymal migrating properties, is important to initiate the metastatic cascade allowing the cancer cells to leave the primary tumor. However, recent studies had challenged this notion. Consequently, the importance of EMT for metastasis is still unclear. Does the EMT requirement depend on the tumor type? Does EMT occur in the circulating tumor cells? Does EMT revert to an epithelial phenotype at the metastatic sites?

In a study published in Cell Reports, researchers lead by Pr. Cédric Blanpain, MD/PhD, WELBIO investigator and Professor at the Université Libre de Bruxelles, Belgium had now provided evidence that the tumor cells that initiate the metastatic process undergo EMT and that the reverse transition called MET is occurring at the metastatic site, underscoring the importance of tumor cell state transitions and tumor cell plasticity during the metastatic process.

To resolve whether EMT is required for metastasis, they used two distinct models of skin squamous cell carcinoma (SCC) undergoing or not spontaneous EMT during tumorigenesis. The mouse model in which the tumors displayed EMT presented high metastatic incidence. In sharp contrast the SCC model without EMT presents very low incidence of metastasis, supporting the notion that EMT is important for metastasis.

Circulating tumor cells (CTCs) is one of the first steps in metastatic cascade. Up to now CTCs are detected based on the expression of epithelial markers such as Epcam, the gold standard and is used in clinic to evaluate the number of CTCs to predict metastasis and response to therapy. Our genetic model tracking the cancer cells based on the expression of fluorescent protein allowed the researcher to determine the presence of CTCs, regardless the expression of known markers. They found that CTCs were always associated with metastases. However, the vast majority of CTCs were Epcam-negative. This finding suggests that CTC needs to undergo EMT to form metastasis and that the use of Epcam marker to track CTCs is not optimal. "Clearly new methods using novel markers that recognize CTC that underwent EMT would be required to better monitor CTCs in the blood of cancer patients", comments Tatiana Revenco, the first author of this study.

Importantly, the researchers observed that the majority of metastases present little signs of EMT, supporting the notion that the reversion of EMT, called MET is important for the metastatic outgrowth. "This finding is very important to take into consideration when applying anti-EMT treatment, as it can prevent the metastatic dissemination from primary tumor but can favor the metastatic growth in distant organs" comments Pr Blanpain, the last and corresponding author of the study.
-end-
This work was supported by the WELBIO, the Belgian Foundation against cancer, the FNRS, the TELEVIE, the Fondation ULB, the foundation Baillet Latour, the foundation Julie et Francoise Drion, and the worldwide cancer research.

Université libre de Bruxelles

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.